Renal protection of levosimendan in patients undergoing coronary artery bypass grafting combined with valve replacement
Fan Zhen
Lin Peirong
Zhao Liyun
Ma Jun
Abstract：Objective To explore the renal protection of levosimendan in patients undergoing coronary artery bypass grafting combined with valve replacement.Methods Thirty patients with severe cardiac dysfunction (left ventricular ejection fraction ＜ 50％) undergoing coronary artery bypass grafting combined with valve replacement from January to December 2016 in Beijing Anzhen Hospital,Capital Medical University were randomly divided into observation group and control group,with 15 cases in each group.The observation group had intravenous infusion of levosimendan after anesthesia induction;the control was treated with routine vasoactive agents.Levels of blood lactate,urea nitrogen and creatinine were tested before and 6,12,24,48,72 h after operation.Urine volume was recorded during and after operation.Postoperative 24 h drainage volume,mechanical ventilation time,intensive care time stay time and hospital stay time were recorded.Results Urine volume during operation and 6,12,24 h after operation in observation group were significantly more than those in control group [(1 713 ± 458) ml vs (1 257 ±489) ml,(1 812 ±442) ml vs (1 192 ±339)ml,(2 749 ±696)ml vs (1 793 ±329)ml,(4 036 ±805) ml vs (3 186 ± 615) ml] (P ＜ 0.05).Levels of blood lactate 12,24,48 h after operation in observation group were significantly lower than those in control group[(4.10 ±2.28) mmol/L vs (6.18 ±3.45) mmol/L,(2.10 ± 1.05) mmol/L vs (4.60 ± 1.86) mmol/L,(1.90 ± 0.95) mmol/L vs (4.90 ± 2.94) mmol/L] (P ＜ 0.05).Levels of blood urea nitrogen 6,12,24 h after operation in observation group were significantly lower than those in control group[(6.5 ± 1.4) mmol/L vs (15.5 ± 7.4) mmol/L,(7.3 ± 1.5) mmol/L vs (15.5 ± 7.4) mmoL/L,(7.6 ± 1.8) mmol/L vs (9.7 ± 2.1) mmol/L] (P ＜ 0.05).Levels of serum creatinine 24,48 h after operation in observation group were significantly lower than those in control group [(92 ± 14) μmol/L vs (106 ± 15) μmol/L,(93 ±25) μmol/L vs (107 ±32) μmol/L] (P ＜0.05).Postoperative 24 h drainage volume,mechanical ventilation time,intensive care time and hospital stay time had no significant differences between groups (P ＞ 0.05).Conclusion Levosimendan can help reduce renal injury in patients undergoing coronary artery bypass grafting and valve replacement.
Keywords：Coronary artery bypassValve replacementLevosimendanRenal protection
Publication Date：2018-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 196-199 )